Biointerface-Engineered Hybrid Nanovesicles for Targeted Reprogramming of Tumor Microenvironment

© 2024 Wiley‐VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 36(2024), 41 vom: 01. Okt., Seite e2401495
1. Verfasser: Zhen, Xueyan (VerfasserIn)
Weitere Verfasser: Li, Yongjiang, Yuan, Wanqing, Zhang, Tingting, Li, Min, Huang, Jinhai, Kong, Na, Xie, Xiaoyu, Wang, Sicen, Tao, Wei
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article M1‐like macrophage antitumor therapy exosome hypoxia alleviation tumor microenvironment reprogramming tumor‐associated macrophage Liposomes Aptamers, Nucleotide Antineoplastic Agents Reactive Oxygen Species
LEADER 01000caa a22002652c 4500
001 NLM373400527
003 DE-627
005 20250306070608.0
007 cr uuu---uuuuu
008 240609s2024 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202401495  |2 doi 
028 5 2 |a pubmed25n1243.xml 
035 |a (DE-627)NLM373400527 
035 |a (NLM)38851884 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Zhen, Xueyan  |e verfasserin  |4 aut 
245 1 0 |a Biointerface-Engineered Hybrid Nanovesicles for Targeted Reprogramming of Tumor Microenvironment 
264 1 |c 2024 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 10.10.2024 
500 |a Date Revised 10.10.2024 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2024 Wiley‐VCH GmbH. 
520 |a The tumor microenvironment (TME) of typical tumor types such as triple-negative breast cancer is featured by hypoxia and immunosuppression with abundant tumor-associated macrophages (TAMs), which also emerge as potential therapeutic targets for antitumor therapy. M1-like macrophage-derived exosomes (M1-Exos) have emerged as a promising tumor therapeutic candidate for their tumor-targeting and macrophage-polarization capabilities. However, the limited drug-loading efficiency and stability of M1-Exos have hindered their effectiveness in antitumor applications. Here, a hybrid nanovesicle is developed by integrating M1-Exos with AS1411 aptamer-conjugated liposomes (AApt-Lips), termed M1E/AALs. The obtained M1E/AALs are loaded with perfluorotributylamine (PFTBA) and IR780, as P-I, to construct P-IM1E/AALs for reprogramming TME by alleviating tumor hypoxia and engineering TAMs. P-I@M1E/AAL-mediated tumor therapy enhances the in situ generation of reactive oxygen species, repolarizes TAMs toward an antitumor phenotype, and promotes the infiltration of T lymphocytes. The synergistic antitumor therapy based on P-I@M1E/AALs significantly suppresses tumor growth and prolongs the survival of 4T1-tumor-bearing mice. By integrating multiple treatment modalities, P-I@M1E/AAL nanoplatform demonstrates a promising therapeutic approach for overcoming hypoxic and immunosuppressive TME by targeted TAM reprogramming and enhanced tumor photodynamic immunotherapy. This study highlights an innovative TAM-engineering hybrid nanovesicle platform for the treatment of tumors characterized by hypoxic and immunosuppressive TME 
650 4 |a Journal Article 
650 4 |a M1‐like macrophage 
650 4 |a antitumor therapy 
650 4 |a exosome 
650 4 |a hypoxia alleviation 
650 4 |a tumor microenvironment reprogramming 
650 4 |a tumor‐associated macrophage 
650 7 |a Liposomes  |2 NLM 
650 7 |a Aptamers, Nucleotide  |2 NLM 
650 7 |a Antineoplastic Agents  |2 NLM 
650 7 |a Reactive Oxygen Species  |2 NLM 
700 1 |a Li, Yongjiang  |e verfasserin  |4 aut 
700 1 |a Yuan, Wanqing  |e verfasserin  |4 aut 
700 1 |a Zhang, Tingting  |e verfasserin  |4 aut 
700 1 |a Li, Min  |e verfasserin  |4 aut 
700 1 |a Huang, Jinhai  |e verfasserin  |4 aut 
700 1 |a Kong, Na  |e verfasserin  |4 aut 
700 1 |a Xie, Xiaoyu  |e verfasserin  |4 aut 
700 1 |a Wang, Sicen  |e verfasserin  |4 aut 
700 1 |a Tao, Wei  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 36(2024), 41 vom: 01. Okt., Seite e2401495  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnas 
773 1 8 |g volume:36  |g year:2024  |g number:41  |g day:01  |g month:10  |g pages:e2401495 
856 4 0 |u http://dx.doi.org/10.1002/adma.202401495  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 36  |j 2024  |e 41  |b 01  |c 10  |h e2401495